Objective: To assess longitudinally cognitive functioning in relapsing—remitting multiple sclerosis (RRMS) patients and its relationship with clinical and MRI variables.
Methods: Early RRMS patients and matched healthy controls were assessed in parallel in three testing sessions over 3 years, using the Rao’s Brief Repeatable Battery of Neuropsychological Tests. Patients also underwent an MRI analysis of T2-weighted lesion volume (T2LV), number of gadolinium-enhanced lesions and whole brain atrophy. Forty-nine RRMS patients (mean age 36.9 ± 8.9 years; mean disease duration 2.9 ± 1.7 years, mean Expanded Disability Status Scale, 1.7 ± 0.7) and 56 healthy controls were recruited.
Results: At baseline, cognitive impairment was detected in 15 patients (30.6%). After 3 years, cognitive functioning worsened in the 29.3% of patients, whereas Expanded Disability Status Scale progression was observed in only three patients. The most sensitive test to detect cognitive deterioration over time was the Symbol Digit Modalities Test (SDMT). Only the presence of moderate cognitive impairment at baseline predicted further cognitive deterioration (p = 0.03). Among MRI variables, T2LV showed a weak to moderate relationship with some cognitive tasks.
Conclusions: Over a 3-year period cognitive deterioration can be expected in approximately one-third of MS patients with relatively short disease duration. The SDMT is particularly suitable for longitudinal assessment of MS-related cognitive changes.
Amato MP, Zipoli V. and Portaccio E.Cognitive changes in multiple sclerosis. Expert Rev Neurother2008; 8: 1585- 1596.
2.
Amato MP, Ponziani G., Siracusa G. and Sorbi S.Cognitive dysfunction in early-onset multiple sclerosis: a reappraisal after 10 years. Arch Neurol2001; 58: 16021606.
3.
Zivadinov R. , Sepcic J., Nasuelli D., et al. A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing remitting multiple sclerosis. J Neurol Neurosurg Psychiatry2001 ; 70: 773780.
4.
Camp SJ, Stevenson VL, Thompson AJ, et al. A longitudinal study of cognition in primary progressive multiple sclerosis. Brain2005; 128: 28912898.
5.
Kujala P., Portin R. and Ruutiainen J.The progress of cognitive decline in multiple sclerosis. A controlled 3-year follow-up. Brain1997; 120: .
6.
Jennekens-Schinkel A., Laboyrie PM, Lanser JB and van der Velde EACognition in patients with multiple sclerosis after four years. J Neurol Sci1990; 99: 229247 .
7.
Mariani C., Farina E., Cappa SF, et al. Neuropsychological assessment in multiple sclerosis: a follow-up study with magnetic resonance imaging. J Neurol1991; 238: 395400 .
8.
Hohol MJ, Guttmann CR, Orav J., et al. Serial neuropsychological assessment and magnetic resonance imaging analysis in multiple sclerosis. Arch Neurol1997; 54: 1018-1025 .
9.
Filley CM, Heaton RK, Nelson LM, Burks JS and Franklin GMA comparison of dementia in Alzheimer’s disease and multiple sclerosis . Arch Neurol1989; 46: 157-161 .
10.
Rosti E., Hamalainen P., Koivisto K. and Hokkanen L.One-year follow-up study of relapsing remitting MS patients’ cognitive performances: Paced Auditory Serial Addition Test’s susceptibility to change. J Int Neuropsychol Soc2007; 13: 791-798 .
11.
Feinstein A. , Brown R. and Ron M.Effects of practice of serial tests of attention in healthy subjects. J Clin Exp Neuropsychol1994; 16: 436-447 .
12.
Feinstein A. , Ron M. and Thompson A.A serial study of psychometric and magnetic resonance imaging changes in multiple sclerosis. Brain1993; 116: 569-602 .
13.
Weinstein A. , Schwid SR, Schiffer RB, McDermott MP, Giang DW and Goodman ADNeuropsychologic status in multiple sclerosis after treatment with glatiramer. Arch Neurol1999; 56: 319-324 .
14.
Fischer JS, Priore RL, Jacobs LD, et al. Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group. Ann Neurol2000; 48: 885-892 .
15.
Poser CM, Paty DW, Scheinberg L., et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol1983; 13: 227-231 .
16.
Kurtzke JFRating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology1983; 33: 1444-1452 .
17.
Rao S.A manual for the Brief Repeatable Battery of Neuropsychological Tests in multiple sclerosis. Milwaukee, WI: Medical College of Wisconsin, 1990.
18.
Barbarotto R. , Laiacona M., Frosio R., Vecchio M., Farinato A. and Capitani E.A normative study on visual reaction times and two Stroop colour-word tests. Ital J Neurol Sci1998; 19: 161-170 .
19.
Montgomery SA and Asberg M.A new depression scale designed to be sensitive to change. Br J Psychiatry1979; 134: 382-389 .
20.
Krupp LB, LaRocca NG, Muir-Nash J. and Steinberg ADThe fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol1989; 46: 1121-1123 .
21.
Smith SM, De Stefano N., Jenkinson M. and Matthews PMNormalized accurate measurement of longitudinal brain change. J Comput Assist Tomogr2001; 25: 466-475 .
22.
Smith SM, Zhang Y., Jenkinson M., et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage2002; 17: 479-489 .
23.
Camp SJ, Stevenson VL, Thompson AJ, et al. Cognitive function in primary progressive and transitional progressive multiple sclerosis: a controlled study with MRI correlates. Brain1999; 122: 1341-1348 .
24.
Jacobson NS and Truax P.Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol1991; 59: 12-19 .
25.
Martin R., Griffith HR, Sawrie S., Knowlton R. and Faught E.Determining empirically based self-reported cognitive change: development of reliable change indices and standardized regression-based change norms for the multiple abilities self-report questionnaire in an epilepsy sample . Epilepsy Behav2006; 8: 239-245 .
26.
Amato MP, Portaccio E., Goretti B., et al. The Rao’s Brief Repeatable Battery and Stroop Test: normative values with age, education and gender corrections in an Italian population . Mult Scler2006; 12: 787-793 .
27.
Achiron A. and Barak Y.Cognitive impairment in probable multiple sclerosis. J Neurol Neurosurg Psychiatry2003; 74: 443-446 .
28.
Glanz B., Holland C., Gauthier S., et al. Cognitive dysfunction in patients with clinically isolated syndromes or newly diagnosed multiple sclerosis. Mult Scler2007; 13: 1004-1010 .
29.
Deloire MS, Bonnet MC, Salort E., et al. How to detect cognitive dysfunction at early stages of multiple sclerosis?Mult Scler2006; 12: 445-452 .
30.
Pliskin NH, Hamer DP, Goldstein DS, et al. Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-1b. Neurology1996; 47: 1463-1468 .
31.
Freedman MS , Kappos L., Polman CH, et al. Impact of early interferon beta-1b treatment on disease evolution over five years in patients with a first event suggestive of multiple sclerosis. Mult Scler2008; 14: S295-S296.
32.
Benedict RH , Duquin JA, Jurgensen S., et al. Repeated assessment of neuropsychological deficits in multiple sclerosis using the Symbol Digit Modalities Test and the MS Neuropsychological Screening Questionnaire. Mult Scler2008; 14: 940-946 .
33.
Drake A., Weinstock-Guttman B., Morrow S., Hojnacki D., Munschauer F. and Benedict R.Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test. Mult Scler, 2010; 16(2): 228-237 .
34.
Arnett PA, Rao SM, Bernardin L., Grafman J., Yetkin FZ and Lobeck L.Relationship between frontal lobe lesions and Wisconsin Card Sorting Test performance in patients with multiple sclerosis. Neurology1994; 44: 420-425 .
35.
Foong J., Rozewicz L., Quaghebeur G., et al. Executive function in multiple sclerosis. The role of frontal lobe pathology. Brain1997; 120: 15-26 .
36.
Rao SM, Leo GJ, Haughton VM, St Aubin-Faubert P. and Bernardin L.Correlation of magnetic resonance imaging with neuropsychological testing in multiple sclerosis. Neurology1989; 39: 161-166 .
37.
Swirsky-Sacchetti T., Mitchell DR, Seward J., et al. Neuropsychological and structural brain lesions in multiple sclerosis: a regional analysis. Neurology1992; 42: 1291-1295 .
38.
Rovaris M., Filippi M., Falautano M., et al. Relation between MR abnormalities and patterns of cognitive impairment in multiple sclerosis. Neurology1998; 50: 1601-1608 .
39.
Rovaris M., Comi G. and Filippi M.MRI markers of destructive pathology in multiple sclerosis-related cognitive dysfunction. J Neurol Sci2006; 245: 111-116 .
40.
Benedict RH , Bruce JM, Dwyer MG, et al. Neocortical atrophy, third ventricular width, and cognitive dysfunction in multiple sclerosis. Arch Neurol2006; 63: 1301-1306 .
41.
Benedict RH , Zivadinov R., Carone DA, et al. Regional lobar atrophy predicts memory impairment in multiple sclerosis. AJNR Am J Neuroradiol2005; 26: 1824-1831 .
42.
Amato MP, Bartolozzi ML, Zipoli V., et al. Neocortical volume decrease in relapsing remitting MS patients with mild cognitive impairment. Neurology2004; 63: 89-93
43.
Amato MP, Portaccio E., Goretti B., et al. Association of neocortical volume changes with cognitive deterioration in relapsing remitting multiple sclerosis. Arch Neurol2007; 64: 1157-1161 .
44.
Houtchens MK , Benedict RH, Killiany R., et al. Thalamic atrophy and cognition in multiple sclerosis. Neurology2007; 69: 1213-1223 .
